Naltriben methanesulfonate is a highly selective DOR (δ2 opioid receptor ) antagonist. Ligand binding assays show biphasic binding of the antagonist to the single receptor type.
Szekeres, P.G., Traynor, J.R., Delta opioid modulation of the binding of guanosine-5′-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J. Pharmacol. Exp. Ther. 283, 1276, (1997) Abstract Takemori, A.E., et al., Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone. Life Sci. 50, 1491-1495, (1992) Abstract Miyamoto, Y., et al., Involvement of δ2 opioid receptors in the development of morphine dependence in mice. J. Pharmacol. Exp. Ther. 264, 1141-1145, (1993) Abstract
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.